Comparative trial of BBR 2778 (pixantrone) plus rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).

被引：0
|
作者：
Santoro, A.
Voglova, J.
Gabrail, N.
Ciuleanu, T.
Liberati, M.
Hancock, B. W.
Stromatt, S.
Caballero, D.
机构：
[1] Ist Clin Humanitas, Rozzano, Italy
[2] Internal Clin, Dept Clin Haematol, Hradec Kralove, Czech Republic
[3] Gabrail Canc Ctr, Canton, OH USA
[4] Inst Oncol, Cluj Napoca, Romania
[5] Univ Perugia, I-06100 Perugia, Italy
[6] Weston Pk Hosp, Sheffield, S Yorkshire, England
[7] Cell Therapeut Inc, Seattle, WA USA
[8] Hosp Clin Salamanca, Serv Hematol, Salamanca, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：441S / 441S
页数：1
相关论文
共 50 条
  • [41] Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysis
    Zhang, Peng-Fei
    Xie, Dan
    Wen, Feng
    Li, Qiu
    CANCER MEDICINE, 2020, 9 (15): : 5312 - 5319
  • [42] Rituximab in the treatment of non-Hodgkin's lymphoma
    Hauptrock, Beate
    Hess, Georg
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 619 - 633
  • [43] Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide plus rituximab (R2) vs. rituximab plus placebo in relapsed/refractory indolent non-Hodgkin lymphoma
    Izutsu, Koji
    Minami, Yosuke
    Fukuhara, Noriko
    Terui, Yasuhito
    Jo, Tatsuro
    Yamamoto, Go
    Ishikawa, Takayuki
    Kobayashi, Tsutomu
    Kiguchi, Toru
    Nagai, Hirokazu
    Ohtsu, Tomoko
    Kalambakas, Stacey
    Fustier, Pierre
    Midorikawa, Shuichi
    Tobinai, Kensei
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (03) : 409 - 416
  • [44] Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial
    Mehta, Amitkumar
    Popplewell, Leslie
    Collins, Graham P.
    Smith, Sonali M.
    Flinn, Ian W.
    Bartlett, Nancy L.
    Ghosh, Nilanjan
    Hacohen-Kleiman, Gal
    Huo, Yanan
    Su-Feher, Linda
    Renard, Camille
    Advani, Ranjana
    Roschewski, Mark
    BLOOD ADVANCES, 2024, 8 (22) : 5855 - 5863
  • [45] Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma:: a single-centre study of 20 patients
    Aydin, Semra
    Duehrsen, Ulrich
    Nueckel, Holger
    ANNALS OF HEMATOLOGY, 2007, 86 (04) : 271 - 276
  • [46] Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma: a single-centre study of 20 patients
    Semra Aydin
    Ulrich Dührsen
    Holger Nückel
    Annals of Hematology, 2007, 86 : 271 - 276
  • [47] Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma
    Leonard, JP
    Coleman, M
    Ketas, J
    Ashe, M
    Fiore, JM
    Furman, RR
    Niesvizky, R
    Shore, T
    Chadburn, A
    Horne, H
    Kovacs, J
    Ding, CL
    Wegener, WA
    Horak, ID
    Goldenberg, DM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 5044 - 5051
  • [48] Gemcitabine as single agent in the treatment of relapsed and refractory Hodgkin's and non-Hodgkin lymphoma.
    Jajeh, A
    Hadad, L
    Zalzaleh, G
    Ruestow, P
    BLOOD, 2003, 102 (11) : 285B - 285B
  • [49] Optimizing the clinical benefit of rituximab - in indolent non-Hodgkin's lymphoma
    不详
    CLINICAL LYMPHOMA, 2004, 5 (03): : 149 - 151
  • [50] Cost effectiveness of rituximab plus CVP in previously untreated indolent non-Hodgkin's lymphoma
    Maturi, B.
    Tong, W.
    Gyldmark, M.
    Creeden, J.
    Aultman, R.
    Jost, F. F.
    VALUE IN HEALTH, 2006, 9 (06) : A288 - A288
12345